Derma Sciences (NASDAQ: DSCI) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its peers? We will compare Derma Sciences to similar businesses based off the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Derma Sciences and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Derma Sciences 0 1 0 0 2.00
Derma Sciences Competitors 415 2177 3382 122 2.53

All “Advanced Medical Equipment & Technology” companies have a potential downside of 20.80%. Given Derma Sciences’ peers stronger consensus rating and higher probable upside, analysts clearly believe Derma Sciences has less favorable growth aspects than its peers.

Profitability

This table compares Derma Sciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Derma Sciences -20.97% -17.10% -12.43%
Derma Sciences Competitors -350.27% -33.57% -13.23%

Insider & Institutional Ownership

58.9% of Derma Sciences shares are owned by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 9.9% of Derma Sciences shares are owned by insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Derma Sciences and its peers top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Derma Sciences N/A N/A -17.50
Derma Sciences Competitors $2.01 billion $429.46 million -57.72

Derma Sciences’ peers have higher revenue and earnings than Derma Sciences. Derma Sciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently the more expensive than other companies in its industry.

Volatility & Risk

Derma Sciences has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Derma Sciences’ peers have a beta of 0.89, meaning that their average stock price is 11% less volatile than the S&P 500.

Summary

Derma Sciences peers beat Derma Sciences on 6 of the 11 factors compared.

Derma Sciences Company Profile

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company’s traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.